Bausch & Lomb could go public (again); FDA accepts Alexza's NDA for Adasuve;

 @FierceBiotech: Pfizer inks licensing deal with Russia's SatRx for diabetes drug. Release | Follow @FierceBiotech

 @JohnCFierce: So K-V says that if the FDA doesn't ride to its rescue on Makena comp, it's going bankrupt in a few months. Buh-bye. More | Follow @JohnCFierce

 @RyanMFierce: Interesting biotech startup opportunity: nanoparticles that reduce amount of active drug needed combat clots. More | Follow @RyanMFierce

> After going private in 2007, device and drug company Bausch & Lomb might decide to hop back aboard the public markets, unnamed sources told The Wall Street Journal. Article

> After losing a legal battle to cut ties with marketing partner Takeda Pharmaceutical, Sucampo Pharmacueticals ($SCMP) is reaching out to the company. More

> Alexza Pharmaceuticals ($ALXA) said that the FDA has accepted drug developer's latest NDA for the antipsychotic drug Adasuve and gave the company a PDUFA data of Dec. 21, 2012. Item

> Xconomy takes a look at Novo Nordisk's plans for an R&D facility in Seattle. Article

Pharma News

 @FiercePharma: Top EMA lawyer jumps ship for SIdley Austin, private firm repping pharma companies. Agency investigates--FT. More | Follow @FiercePharma

> Pfizer trimming health claims on Centrum. Story

> NICE turns down Avastin for breast cancer. News

> K-V says it will go bankrupt without FDA intervention. Article

Medical Device News

@FierceMedDev: While purchasers praise the FDA's device ID plan, members of the industry remain wary. Item | Follow @FierceMedDev

 @MarkHFierce: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @MarkHFierce

 @DamianFierce: Roche gets its second FDA diagnostic approval this week, this time for a virus test. Story | Follow @DamianFierce

> Purchasers praise device ID plan, AdvaMed remains wary. News

> r4 Vascular nabs 510(k) for quick-inflate balloon catheter. More

> Roche gets FDA approval for cytomegalovirus diagnostic. Article

> FDA device unit looking out for 'Twilight' fans' eyes. More

And Finally… Harvard scientists have designed drug-coated nanoparticles that can combat clots and could serve as vehicles for other treatments. Report

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.